CDNA

CareDx's stock has shown significant activity, increasing by 272.38% over the last 12 months, 188.38% year-to-date, and 11.77% in the past month. Key events include strong Q2 2026 financial results announced on July 30, 2026, with revenue increasing 52% year-over-year to $132 million, exceeding expectations and leading to a 14-15% stock jump and raised full-year guidance. On July 16, 2026, Medicare finalized its coverage policy for AlloSure and AlloMap, supporting patient access and contributing to a +35.60% daily stock move. CareDx completed the acquisition of Naveris on July 7, 2026, expanding into specialty oncology and cell therapy. The company also divested its Lab Products business to Eurobio Scientific for $170 million on June 30, 2026, recognizing a $113 million gain and enhancing financial flexibility.